Last reviewed · How we verify

NCT07418242

Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients

Recruiting now Last updated 24 February 2026
What this trial tests

trial testing Standard care "bundle" in Cardiac Surgery Associated - Acute Kidney Injury in 1,491 participants. Currently enrolling.

Timeline
23 February 2026
Primary endpoint
31 December 2028
31 May 2029

Quick facts

Lead sponsorGuowei Tu
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,491
Start date23 February 2026
Primary completion31 December 2028
Estimated completion31 May 2029
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Guowei Tu

Who can join

Adults 18 to 90, any sex, with Cardiac Surgery Associated - Acute Kidney Injury or Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to detect novel biomarkers from preoperative and early postoperative serum and urine samples of patients to screen and analyze the risk factors for predicting adverse postoperative renal outcomes in high-risk patients in cardiac surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Standard care "bundle"

Trials testing the same drug.

Other recruiting trials for Cardiac Surgery Associated - Acute Kidney Injury

Currently open trials in the same condition.

Other Guowei Tu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07418242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing